

# INTREPID Alliance Antiviral Landscape: Overview of 13 Priority Viral Families\*

As of July 12, 2024, for the 13 viral families with greatest risk of pandemic potential, clinical phase & approved antiviral compounds fall into 9 of 13 and preclinical into 10 of 13.

## Primarily Respiratory Transmission:

Viral Family	Disease Indication (n)**	
	Preclinical	Clinical
Adenoviridae	HuAdeno A-G (3)	HuAdeno A-G (0)
Coronaviridae	COVID-19 (73) MERS-CoV (5) SARS-CoV-1 (5)	COVID-19 (29)
Orthomyxoviridae	Influenza (12)	Influenza (9)
Paramyxoviridae	Hendra virus (3) Measles (1) Nipah virus (3) Parainfluenza (0)	X
Picornaviridae	X	Polio (2) Rhinovirus (1)

**X** = absence of preclinical or clinical phase antivirals

## Primarily Contact/Vector-Mediated Transmission:

Viral Family	Disease Indication (n)**	
	Preclinical	Clinical
Arenaviridae	Lassa fever (1) Argentine hem. fever (0) Luján hem. fever (0)	Lassa fever (1) Chapare hem. fever (1)
Filoviridae	Ebola (1) Marburg (3)	Ebola (2)
Flaviviridae	Dengue (4) West Nile (1) Yellow fever (3) Zika (2)	Dengue (3) Japanese encephalitis (0)
Hantaviridae	Hantavirus (1)	X
Nairoviridae	X	Crimean Congo hem. fever (2)
Peribunyaviridae	X	X
Poxviridae	Mpox (2) Smallpox/Other poxviruses (1)	Mpox (1)
Togaviridae	Chikungunya (3)	X

\*As of July 12, 2024; \*\*Number of compounds in ongoing development; those with (0) only have “Archived” compounds.

# Preclinical Compounds by Stage of Preclinical Development: COVID-19 Indications

The majority of preclinical compounds are under evaluation for SARS-CoV-2/COVID-19 (72/106, 68%).

COVID-19 Preclinical Compound/Indications (n=72)

Hit (35)		Early Lead (16)		Late Lead (11)		Potential Candidate (10)	
6-72-2a	Anisodamine	21i	666-15	2-Thiouridine	3N39v4-Fc	CDI-45205	CDI-873
AVI-8053	Borneol Ester, PROTACs	C6G255	D6	Beta-521	DCOY 102/103	COR803	COV-X
CD048725C	Epigallocatechin-3-gallate	EDDC-2214	EK1C4	HT-002	Jun12682	MDL-001	NV-CoV-2-R
H84T-BanLec	IPB02	FBP (frog-defensin-derived basic peptide)	NBCoV63	LNA ASOs	ML2006a4	P315V3	RCYM003
IPB19	Lycium barbarum glycopeptide	PLpro Inhibitors	RCYM002	Mpro inhibitor	MVR-V001	SY110	THY-01
MCULE-5948770040	MPI5	SBCoV202	Small molecule inhibitor	PF-07957472			
MPI8	MRX-18	STI 4398	SWC423				
MXB-4	MXB-9	Therapeutic interfering particles	TNX-3500				
Napthoquinones	Pan-coronavirus broad spectrum antiviral						
Penciclovir	Pentosan Polysulfate						
Protegrin-2	RECCE 529						
SACT-Covid19	Sangivamycin						
Saquinavir	SARS-CoV-2 PLpro Inhibitor						
SBFM-PL4	SPIKENET						
Spirooxindole	SSYA10-001						
TEAR-CoV	Urtica dioica agglutinin (UDA)						
VirusAL	YH-6						
ZINC000000639429							

\*As of July 12, 2024; Archived compounds are not included in this summary.

# Preclinical Compounds by Stage of Preclinical Development: Non-COVID-19 Indications

For Non-COVID-19 preclinical compounds, Influenza has the highest number under evaluation (12/34, 35%).

Non-COVID-19 Preclinical Compound/Indications (n=34)

Hit (14)

MLT202	SRI-42718
KCB261770	Pan-coronavirus broad spectrum antiviral
SSYA10-001	Pan-coronavirus broad spectrum antiviral
SSYA10-001	Pan-flavivirus broad spectrum antiviral
Pan-flavivirus broad spectrum antiviral	Dengue antiviral (Protinhi)
MLT201	Pan-flavivirus broad spectrum antiviral
ALS-1	T-1106 pronucleotides

Early Lead (10)

Chikungunya antiviral	NBCoV63
NBCoV63	DCOY3001 Pan-paramyxovirus
Compound 23b	Influenza A/B Inhibitor
IY7640	M355
OA-10 (oleanolic acid)	VTose

Late Lead (6)

ERDRP-0519	VIKI-dPEG4-toco
VIKI-PEG4-chol	2-Thiouridine
ING-1466	UAWJ280

Potential Candidate (4)


THY-01	THY-01
AnQlar	VNT-101

## Indication Legend

COVID-19	Dengue	Hendra virus	Influenza
Chikungunya	Measles	MERS-CoV	Nipah virus
SARS-CoV-1	West Nile virus	Zika	

\*As of July 12, 2024; Archived compounds are not included in this summary.


# # Preclinical Compound/Indications by Viral Family (Non-COVID-19; N=56)\*



- ▶ Ten of the 13 viral families with pandemic potential have preclinical compound/indications.
- ▶ *Orthomyxoviridae* has the most compounds and is focused on Influenza.

\*As of July 12, 2024


# # Preclinical Compound/Indications by Stage of Preclinical Development and Viral Family (Non-COVID-19; N=56)\*



- ▶ Compound/Indications span the various stages of preclinical development.
  - ▶ *Orthomyxoviridae* (Influenza) has the most compound/indications.

\*As of July 12, 2024


# # Preclinical Compound/Indications by Viral Family and Stage of Preclinical Development (Non-COVID-19; N=56)\*



- ▶ Compound/Indications span the various stages of preclinical development.
- ▶ The majority (12/46, 27%) are focused on *Orthomyxoviridae* (Influenza).


\*As of July 12, 2024

# # Preclinical Compound/Indications by Viral Disease and Stage of Preclinical Development (Non-COVID-19; N=56)\*



\*As of July 12, 2024

# Preclinical Compound/Indications by Stage of Preclinical Development and Viral Disease (Non-COVID-19; N=56)\*




- ▶ Compound/Indications span the various stages of preclinical development.
- ▶ Most are focused on Influenza.

\*As of July 12, 2024



# COVID-19 Compounds by Stage of Preclinical Development (N=76)\*



\*As of July 12, 2024



INTREPID ALLIANCE

INTERNATIONAL READINESS FOR PREVENTING INFECTIOUS VIRAL DISEASE

**Interested  
in engaging  
with us?**

We welcome all feedback through [our online portal](#). As with previous listings, developers are invited to submit non-confidential information on their compound candidates. All reports are updated quarterly.

For more information, contact [nina@intrepidalliance.org](mailto:nina@intrepidalliance.org).

 [intrepidalliance.org](https://intrepidalliance.org)

 [linkedin.com/company/intrepid-alliance](https://linkedin.com/company/intrepid-alliance)